Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib plus R-CHOP versus placebo plus R-CHOP in untreated non-GCB diffuse large B-cell lymphoma in adults aged 65 years or younger
MOH_2020-08-13_009238Phase 3Not yet recruiting
- Sponsor
- Acerta Pharma
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse large B-cell lymphoma (DLBCL) comparing Acalabrutinib plus R-CHOP with Placebo plus R-CHOP (2 arms). Primary endpoint: Progression-free survival. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
acalabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2020-08-13_009238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-13_009238.